T
he integrin ␣L␤2 on leukocytes mediates adhesion and migration in immune responses within lymphoid organs and trafficking of leukocytes in inflammation and homing of lymphocytes within the body. ␣L␤2 binds multiple, related cell surface glycoprotein ligands that are members of the IgSF, including intercellular adhesion molecule-1 (ICA M-1), ICAM-2, and ICAM-3 (1) . Adhesiveness of the extracellular domains of ␣L␤2 is rapidly and dynamically regulated by signals within the cell in a process termed inside-out signaling. Thus, ␣L␤2 can act as an adhesion servomotor controlled by antigen receptors and G protein-coupled chemoattractant receptors during immune responses and cell migration. Both clustering in the membrane (avidity regulation) and receptor conformational change (affinity regulation) have been proposed to regulate adhesiveness of ␣L␤2 (2) (3) (4) (5) (6) (7) (8) .
Integrin ␣␤ heterodimers have a complex domain organization (9) . A ligand binding headpiece that contains domains from both subunits is connected by long C-terminal ␣ and ␤ subunit stalk regions to the membrane. An inserted domain (I domain) that is located in the headpiece of the ␣L subunit is implicated as a critical ligand binding site. However, a ␤-propeller domain in the ␣L subunit and an I-like domain in the ␤2 subunit also have been suggested to contribute to ligand binding (9) . I domains from several different integrin ␣ subunits have been crystallized. The I domain has a dinucleotide binding fold with a central hydrophobic ␤-sheet surrounded by amphipathic ␣-helices, and a metal ion-dependent adhesion site (MIDAS) on the ligand-binding face. Crystal structures for two different I domain conformations, termed open and closed, have been obtained for ␣M and ␣2 I domains, and it has been hypothesized that these represent the ''high affinity'' and ''low affinity'' conformations, respectively (10) (11) (12) . The two conformers differ in the side chains that coordinate the Mg 2ϩ ion in the MIDAS, which is hypothesized to make the Mg 2ϩ ion in the open conformer more electrophilic for an acidic residue from the ligand. Also, in the open conformation, there is a 10-Å movement of the C-terminal ␣-helix down the body of the I domain and a large rearrangement and downward movement of the loop connecting this helix to the preceding ␤-strand. Small G proteins such as Ras are structurally related to I domains and exhibit similar alterations in Mg 2ϩ ion coordination that are coupled to peptide backbone rearrangements (11) .
Disulfides have previously been successfully used to restrict intramolecular mobility and probe conformational change in bacterial chemoreceptors (13, 14) and rhodopsin (15) , as well as to increase the stability of proteins (16) . However, efforts to lock in active conformations with disulfides have been challenging. Rhodopsin has thus far been locked only in the inactive form (15) ; the bacterial aspartate receptor has been locked in forms with up to 4-fold higher enzymatic activity and 8-fold higher affinity for aspartate (17) .
The structure of the ␣L I domain has been determined only in the closed conformation (18) ; however, there is direct evidence for conformational change (19) , and we hypothesized that the ␣L I domain might exist in an open conformation similar to that seen in crystal structures for ␣M (10) and ␣2 (12) I domains. We have introduced disulfide bonds into the ␣L I domain to lock it in the open or closed conformation and examined the consequences for cell adhesion (20, 21) . Here we describe our methodology, directly demonstrate disulfide bond formation, measure the kinetics and affinity of soluble recombinant I domains locked in specific conformations for ICAM-1, ICAM-2, and ICAM-3, and investigate adhesion antagonism in vitro and in vivo. We demonstrate that the conformation of the ␣L I domain dramatically regulates affinity for ligand and that disulfide bond engineering has the potential to increase protein affinity many orders of magnitude more than previously achieved.
Methods
A Model for the Open ␣L I Domain. I domains with the following Protein Data Bank identifiers were structurally superimposed by using C␣ carbons, the three-dimensional MALIGN algorithm of MODELLER 4 (22) and a gap extension penalty of 1 Å: Mac-1, 1ido (10) and 1jlm (11) ; lymphocyte function-associated antigen-1 (LFA-1), 1lfa molecules A and B (18), 1zon and 1zop (23); and VLA-2, 1aox (24) . The algorithm found 121 framework residues that were used for superposition. A second sequence and structure-based alignment also was made. The 1ido and 1jlm Side chains of residues important in binding to ICAM-1 and ICAM-2 are shown with rose-pink side chains and yellow sulfur, red oxygen, and blue nitrogen atoms. These residues, defined as important in species-specific binding to ICAM-1 (43) or by at least a 2-fold effect on binding to ICAM-1 or ICAM-2 upon mutation to alanine (44) , are M140, E146, T175, L205, E241, T243, S245, and K263. Note that these residues surround the Mg 2ϩ ion and are distant from the disulfide. (B-E) Predicted disulfide bonds that are selective for open or closed conformers of the ␣L I domain. The K287C͞K294C mutation (B and D) and L289C͞K294C mutation (C and E) were modeled in both open (B and C) and closed (D and E) I domain conformers. For clarity, only residues 254 -305 of the models are shown. The four models were superimposed by using residues not involved in conformational shifts and are shown in exactly the same orientation. The downward movement of the ␣6 helix in B and C compared with D and E is readily apparent. structures were aligned by sequence, and the sequences of 1lfa molecule A and 1zon were aligned by structural similarity to 1jlm. Using the second alignment, the distances between all C␣ carbons at equivalent sequence positions were calculated by using a Microsoft EXCEL spreadsheet (11) . For use as templates for the high affinity ␣L I domain model, segments from 1lfa molecule A were chosen where differences between all four I domains were small or differences between 1lfa and 1jlm (closed ␣L and ␣M I domains) were greater than between 1ido and 1jlm (open and closed ␣M I domains). Segments from 1ido were chosen when differences between 1ido and 1jlm were greater than between 1lfa and 1jlm. Thus, the template used segments G128 to F136, M154 to L203, F209 to L234, T243 to I255, and E272 to A282 of 1lfa, and segments D140 to F156, G207 to T211, V238 to K245, R266 to R281, and R293 to K315 of 1ido. Models of a putative open form of ␣L were made with MODELLER 4 by using this template, the Mg 2ϩ and water molecules 403 and 404 of 1ido, with heteroatom, water, and hydrogen input turned on, and dynamic Coloumb turned on. The resulting model (lfa_hi.063) followed the template C␣ coordinates closely (rms ϭ 0.12 Å). The QUACHK score (25) is excellent (Ϫ0.135 compared with Ϫ0.215 for the lfa-mac template, Ϫ0.08 for 1ido, and 0.0 for 1lfa). Models also were built in which cysteines were introduced ( Fig. 1 B-E); however, it should be noted that all C␤ atom distances reported here are based on models or structures without introduced disulfides.
Prediction of Novel Disulfide Bonds. The 1lfa and 1zon structures and the lfa_hi.063 model were examined with SSBOND (26) . Residues K287 and K294 in lfa_hi.063 and residues L289 and K294 in 1lfa and 1zon were found to have C␤ atom distances in the range between 3.41 and 4.25 Å that is favorable for disulfide bond formation.
Construction and Expression of the ␣L I Domains.
Wild-type and mutant ␣L I-domains (G128-Y307) in expression vector pET11a (Novagen) were constructed by standard molecular biology techniques. Mutant and wild-type I domains were expressed in Escherichia coli, refolded, and purified as described (27) except 0.1 mM CuSO 4 and 0.1 mM o-phenanthroline were added during refolding to catalyze disulfide bond oxidation.
BIAcore. I domains, ICAMs, or BSA as control were covalently immobilized to the dextran surface of CM5 sensor chips via primary amino groups, using the amine coupling kit (BIAcore, Piscataway, NJ). Analytes were flowed over the sensor chip at 10 l͞min, 25°C. Tris-buffered saline containing either 1 mM MgCl 2 , 1 mM MnCl 2 or 2 mM EDTA was used as running buffer, and 20 mM Tris (pH 8), 0.3 M NaCl, 20 mM EDTA was used to remove bound protein and regenerate the surface. Kinetics were analyzed by BIAEVALUATION 3.0 software. Analysis was done after subtracting bulk change and nonspecific binding. Unless otherwise stated, K D was calculated by Scatchard plots using data at steady state. k off was obtained by curve fitting of the dissociation phase using a 1:1 binding model. k obs was obtained by curve 1 and 2) , open (lanes 3 and 4), and closed (lane 5 and 6) I domains (2.5 g) treated in sample buffer containing 10 mM DTT (lanes 1, 3, and 5) or 10 mM iodoacetamide (lanes 2, 4, and 6) were subjected to SDS͞18% PAGE and Coomassie blue staining. Homing Assay. Homing assay was as described (30) . Intravital Microscopy. Lymphocyte traffic on high endothelial venules of subiliac PLN was directly observed by intravital microscopy as described (30) . After recording the behavior of a control injection of GFP ϩ T lymphocytes under baseline conditions, wild-type or locked open I domain (10 g͞g body weight) was infused, and behavior of a second bolus of GFP ϩ T lymphocytes was recorded. Data were analyzed off-line as described (30) . (Fig. 1 A) . The template for this model consisted of segments of the open ␣M I domain structure in regions where the C␣ backbone differed significantly from the closed ␣M I domain structure and segments of the closed ␣L I domain structure (18) elsewhere. The open ␣L I domain model and two closed ␣L I domain structures were examined with the program SSBOND (26) to find positions where cysteine pairs could be introduced to form conformation-specific disulfides. One pair of residues (K287 and K294) in the open model, and one pair of residues (L289 and K294) in the closed structures, underwent large movements between the two conformers, such that after substitution with cysteine, disulfide bond formation could occur only in one conformer ( Fig. 1 B-E) . These disulfides bridge the C-terminal ␣-helix to the preceding ␤-strand and lock the connecting loop in the two alternative conformations seen in the open and closed structures.
Results

Design of I Domains Locked in
Expression of I Domains and Formation of Disulfide Bonds.
Expression in E. coli, refolding, and formation of disulfide bonds in soluble I domains are described in Methods. Purified I domains were monomeric as shown by gel filtration. Intramolecular disulfide bond formation was confirmed by the decrease in mobility in SDS͞PAGE seen after reduction for the open and closed I domains (Fig. 2, lanes 3-6) but not for the wild-type I domain (Fig. 2, lanes 1 and 2) . , whereas the designed closed and wild-type I domains showed very weak interaction with ICAM-1 (Fig. 3A) . Wild-type and designer I domains at the same protein concentration bound identically to mAb TS1͞22 to the ␣L I domain (not shown). Ligand binding by the designed open I domain was abolished by reduction of the disulfide bond with DTT (Fig. 3A) . Binding also was abolished by EDTA (Fig. 3A) and thus depended on Mg 2ϩ , suggesting that binding of the open I domain is mediated by the MIDAS.
Kinetic constants were measured from the association and dissociation phase in BIAcore; K D was measured by Scatchard plots of binding at plateau (Fig. 3B) and was in good agreement with calculation of K D from k off ͞k on . The affinity of the open I domain for ICAM-1 is 9,000-fold higher than that of the wild-type I domain (Table 1 ). Both an increase in k on and a decrease in k off contributed to this dramatic increase in affinity (Table 1) . These results were confirmed by using the reverse orientation with the I domain immobilized on the sensor chip ( Table 2 ). Increased affinity of the open I domain was completely reversed by reduction of the disulfide bond (Table 1) . By contrast, the K D of the closed I domain was similar to that of wild type and was not changed by reduction with DTT (Table 1) . Thus, conformational change dramatically regulates the affinity of the ␣L I domain for ligand.
We compared binding to three distinct LFA-1 ligands, ICAM-1, ICAM-2, and ICAM-3. The open I domain bound well not only to ICAM-1 but also to ICAM-2 and ICAM-3 (Table 2) , whereas the wild-type I domain bound poorly to all three ligands (data not shown). The affinity is highest for ICAM-1 and lowest for ICAM-3. These results are consistent with the previous conclusion from cell adhesion assays that LFA-1 binds to ICAM-1 stronger than ICAM-2 or ICAM-3 (32).
Antagonist Activity of Locked Open I Domain. The potential to antagonize adhesion with locked open I domains was examined in vitro and in vivo. Open I domains potently antagonized cell adhesion through LFA-1 to ICAM-1 (Fig. 4A) . Although the wild-type I domain can inhibit adhesion (33) , it was much weaker than the open I domain (Fig. 4A) . Furthermore, the open, but not wild-type, I
domain potently blocked LFA-1-and ICAM-1-dependent homotypic aggregation of mouse EL-4 T-lymphoma cells (29) (Fig. 4B) . BIAcore experiments confirmed that the affinity of the locked open human ␣L I domain for murine ICAM-1 was comparable to that for human ICAM-1, with K D of 191 nM.
Lymphocyte homing to PLNs depends on an initial step of rolling through L-selectin and a subsequent step of chemokinetriggered firm adhesion through LFA-1 (1). I domains were infused intraarterially, and homing of GFP transgeneexpressing, naïve T lymphocytes was examined (30) . Homing of lymphocytes to PLNs was significantly reduced (P Ͻ 0.05) after treatment with the locked open I domain compared with the wild-type I domain (Fig. 5A) . Consistent with these results, more lymphocytes remained in the circulation in locked open I domain-treated mice than in wild-type I domain-treated mice (10.0 ϫ 10 5 ͞ml and 5.7 ϫ 10 5 ͞ml, respectively, P Ͻ 0.05). The behavior of lymphocytes in high endothelial venules in PLNs was directly observed by using intravital microscopy (34). Rolling was unaffected by either type of I domain (Fig. 5B) . By contrast, the locked open, but not wild-type, I domain significantly inhibited the conversion of rolling cells to firmly adherent cells (Fig. 5C) . Thus, the locked open I domain specifically blocked LFA-1-dependent T lymphocyte sticking and did not interfere with selectin-dependent T lymphocyte rolling.
Discussion
Our work with designed I domains locked in different conformational states directly demonstrates the importance of conformation for regulating ligand binding by integrins. Locking the I domain open with a disulfide bond bracketing the ␤6-␣6 loop increased affinity for ICAM-1 by 9,000-fold and also greatly increased binding to ICAM-2 and ICAM-3. After reduction of this disulfide, the affinity was reduced to a level comparable to wild type. Furthermore, the affinities of the wild-type, locked closed, and reduced locked open mutants were comparable. These findings strongly suggest that the isolated wild-type I domain exists predominantly in the closed conformation, and that this is the low energy conformation. Furthermore, because only the conformation of the ␤6-␣6 loop is directly restrained by the disulfide, our results show that reshaping of this loop and the concomitant downward movement of the C-terminal ␣-helix are fully sufficient for rearrangement of the MIDAS into a ligand binding configuration. Thus, in intact integrins, a downward pull on the C-terminal ␣-helix of the I domain exerted by neighboring domains would be sufficient to open the ligand binding site. In intact integrins, the C terminus of the I domain connects to the predicted ␤-propeller domain, and this connection is near the ␤-subunit I-like domain (35) . Interactions with these neighboring domains may stabilize the open conformation of the I domain in intact ␣L␤2. Measurements on active ␣L␤2 in solution or on the surface of cells show K D values of 60 nM to 500 nM (2, 36, 37) . Remarkably, the published parameters for ␣L␤2 binding to ICAM-1 determined by BIAcore, k on ϭ 2.24 ϫ 10 The locked open and closed ␣L I domains described here have previously been studied expressed on the cell surface, either as isolated I domains with artificial transmembranous and cytoplasmic domains or within ␣L␤2 heterodimers (20, 21) . In both contexts, the locked open I domains were as active in mediating cell adhesion as maximally activated wild-type ␣L␤2. By contrast, the locked closed I domain constructs were inactive and completely resistant to activating stimuli. Taken together with the measurements on affinity reported here, these studies suggest that conformational change and affinity regulation are required for activation of adhesiveness through ␣L␤2.
Cellular treatments that increase the rate of diffusion of ␣L␤2 augment adhesion through ␣L␤2 and both increase in the rate of diffusion and adhesiveness are associated with clustering of ␣L␤2 in the membrane; therefore, it has been suggested that clustering can augment adhesiveness through avidity modulation in the absence of affinity modulation (4-6, 8, 38) . Furthermore, binding of dimeric or multimeric ICAM-1 and binding of activationdependent mAB to cell surface ␣L␤2 have been reported after some but not other types of stimulation that augment adhesiveness through ␣L␤2 (3, 4, 38) . However, the failure to detect binding of ICAM-1 to cells under certain types of conditions that activate adhesiveness could reflect a lack of sensitivity to intermediate levels of ␣L␤2 affinity, rather than a lack of affinity regulation. We have shown here that the difference in affinity between the open and closed conformations is quite large, We have extended the approach described here to another I domain, that of the ␣M integrin subunit, and have found multiple positions in both the ␣L and ␣M domains where disulfide bonds can be introduced that stabilize the open conformation and increase affinity for ligand (M.S. and T.A.S., unpublished work). Using a different approach, we previously have used computational design to find mutations in the hydrophobic core of the ␣M I domain that stabilize the open and closed conformations (39) . From eight to 13 substitutions in the hydrophobic core were used to stabilize the open conformation (39) . The introduction of a disulfide bond into the ␣M I domain appears to be similarly effective in increasing ligand binding activity as measured both in adhesion assays and in BIAcore (M.S. and T.A.S., unpublished work).
Many biologically and pharmaceutically important proteins exist in two different three-dimensional conformations, and like integrins, have functions that are regulated by conformational change, e.g., G proteins, kinases, and G protein-coupled receptors (40) . Therefore, the ability to reversibly lock a protein fold in an active conformation opens vistas in therapeutics and proteomics. As one example of this, integrins that contain I domains are very important therapeutic targets in inflammation, autoimmunity, and transplantation (41) . We have demonstrated here that locked open I domains are potent adhesion antagonists, both in vitro and in vivo. The locked open ␣L I domain inhibited lymphocyte homing. Furthermore, it inhibited the transition of lymphocytes in lymphoid high endothelial venules from rolling adhesion to firm adhesion, but did not inhibit rolling adhesion. These steps are known to depend on ␣L␤2 and L-selectin, respectively (1, 42) , demonstrating the high specificity of the locked open I domain in vivo. Our results suggest that locked open I domains can be used to demonstrate the importance of specific molecular targets in disease processes and are therapeutic candidates. Receptors locked in high affinity conformations offer many advantages, including discrimination between drugs that bind to ligand binding and allosteric sites (20) . Furthermore, antibodies can be rationally obtained that are specific for activated protein conformations for use in diagnosis and treatment of disease.
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